8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Apr 24, 2026·SEC
Material company update
Apr 22, 2026·SEC
Opus Genetics, Inc.(IRD)Earnings, Financials & Key Ratios
IRD•NASDAQ
Price updated Jun 19, 2026
AboutOpus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.Show more
- Revenue$14M+29.1%
- EBITDA-$39M+37.9%
- Net Income-$50M+13.8%
- EPS (Diluted)-0.80+62.8%
- Gross Margin100%
- EBITDA Margin-271.53%+51.9%
- Operating Margin-271.9%+51.9%
- Net Margin-349.33%+33.3%
- ROE-449.36%-121.2%
IRD Key Insights
Opus Genetics, Inc. (IRD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 83 (top 17%)
✗Weaknesses
- ✗Profits declining 15.0% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 165.0x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when IRD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IRD Price & Volume
Opus Genetics, Inc. (IRD) stock price & volume — 10-year historical chart
Loading chart...
IRD Growth Metrics
Opus Genetics, Inc. (IRD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-29.11%
TTM-12.22%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-82.42%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM32.47%
Return on Capital
10 Years-157.68%
5 Years-74.07%
3 Years-99.98%
Last Year-113.48%
IRD Recent Earnings
Opus Genetics, Inc. (IRD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 5/12 qtrs (45%)
Q2 2026Latest
May 21, 2026Metric
Actual
Est
EPS
$0.19-18.8%
$0.16
Rev
$4M+22.9%
$3M
Q2 2026
May 12, 2026Metric
Actual
Est
EPS
$0.75-368.8%
$0.16
Rev
$2M-26.3%
$3M
Q2 2026
Mar 10, 2026Metric
Actual
Est
EPS
$0.14-27.3%
$0.11
Rev
—
$3M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.12+14.3%
$0.14
Rev
$3M+0.2%
$3M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 21, 2026 | $0.19vs $0.16-18.8% | $4Mvs $3M+22.9% |
| Q2 2026 | May 12, 2026 | $0.75vs $0.16-368.8% | $2Mvs $3M-26.3% |
| Q2 2026 | Mar 10, 2026 | $0.14vs $0.11-27.3% | —vs $3M |
| Q4 2025 | Nov 12, 2025 | $0.12vs $0.14+14.3% | $3Mvs $3M+0.2% |
Based on last 12 quarters of dataView full earnings history →
IRD Peer Comparison
Opus Genetics, Inc. (IRD) competitors in Ophthalmology Therapies and Delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 REPL | 841.41M | 10.19 | -3.32 | -102.69% | 0.18 | |||
 JANX | 867.2M | 14.22 | -7.77 | -5.55% | -5.3% | -11.85% | 0.02 | |
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 |
Compare IRD vs Peers
Opus Genetics, Inc. (IRD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IRD Income Statement
Opus Genetics, Inc. (IRD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 589K | 39.85M | 19.05M | 10.99M | 14.2M | 11.98M |
Revenue Growth % | - | - | - | 6665.7% | -52.2% | -42.3% | 29.15% | -12.22% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.04M |
COGS % of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 589K▲ 0% | 39.85M▲ 6665.7% | 19.05M▼ 52.2% | 10.99M▼ 42.3% | 14.2M▲ 29.1% | 5.95M▲ 0% |
Gross Margin % | - | - | 100% | 100% | 100% | 100% | 100% | 49.64% |
Gross Profit Growth % | - | - | - | 6665.7% | -52.2% | -42.3% | 29.15% | - |
Operating Expenses | 4.19M | 19.97M | 23.29M | 21.62M | 29.61M | 73.07M | 52.8M | 48.98M |
OpEx % of Revenue | - | - | 3954.84% | 54.26% | 155.45% | 664.72% | 371.9% | - |
Selling, General & Admin | 1.82M | 2.82M | 8.12M | 7.27M | 11.96M | 18.21M | 21.98M | 21.57M |
SG&A % of Revenue | - | - | 1378.78% | 18.24% | 62.78% | 165.71% | 154.85% | - |
Research & Development | 2.37M | 6.65M | 15.17M | 14.36M | 17.65M | 26.85M | 30.81M | 33.44M |
R&D % of Revenue | - | - | 2576.06% | 36.02% | 92.67% | 244.28% | 217.05% | - |
Other Operating Expenses | 0 | 10.5M | 0 | 0 | 0 | 28M | 0 | -1000K |
Operating Income | -4.19M▲ 0% | -19.97M▼ 376.2% | -22.7M▼ 13.7% | 18.23M▲ 180.3% | -10.56M▼ 158.0% | -62.07M▼ 487.7% | -38.6M▲ 37.8% | -43.03M▲ 0% |
Operating Margin % | - | - | -3854.84% | 45.74% | -55.45% | -564.72% | -271.9% | -359.13% |
Operating Income Growth % | - | -376.22% | -13.71% | 180.27% | -157.96% | -487.65% | 37.82% | - |
EBITDA | -4.19M | -19.96M | -22.7M | 18.23M | -10.56M | -62.06M | -38.55M | -42.98M |
EBITDA Margin % | - | - | -3854.16% | 45.75% | -55.42% | -564.63% | -271.53% | -358.68% |
EBITDA Growth % | - | -376.37% | -13.73% | 180.3% | -157.91% | -487.89% | 37.89% | 32.63% |
D&A (Non-Cash Add-back) | 3K | 8K | 4K | 4K | 6K | 10K | 53K | 53K |
EBIT | -4.76M | -17.77M | -56.69M | 18.21M | -9.97M | -57.53M | -48.13M | -55.78M |
Net Interest Income | -1.41M | -6.85M | -2K | -9K | -1.33M | 0 | -1.47M | -1.35M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 800K |
Interest Expense | 1.41M | 6.85M | 2K | 9K | 1.33M | 0 | 1.47M | 2.15M |
Other Income/Expense | -1.98M | -4.65M | -33.99M | -23K | 589K | 4.54M | -10.99M | -63.9M |
Pretax Income | -6.17M▲ 0% | -24.62M▼ 299.1% | -56.69M▼ 130.3% | 18.2M▲ 132.1% | -9.97M▼ 154.8% | -57.53M▼ 476.8% | -49.59M▲ 13.8% | -106.93M▲ 0% |
Pretax Margin % | - | - | -9625.3% | 45.68% | -52.36% | -523.4% | -349.33% | -892.36% |
Income Tax | 0 | 0 | 0 | 315K | 12K | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 1.73% | -0.12% | 0% | 0% | 0% |
Net Income | -6.17M▲ 0% | -24.62M▼ 299.1% | -56.69M▼ 130.3% | 17.89M▲ 131.6% | -9.99M▼ 155.8% | -57.53M▼ 476.1% | -49.59M▲ 13.8% | -106.93M▲ 0% |
Net Margin % | - | - | -9625.3% | 44.89% | -52.42% | -523.4% | -349.33% | -892.36% |
Net Income Growth % | - | -299.09% | -130.27% | 131.55% | -155.83% | -476.13% | 13.8% | -82.42% |
Net Income (Continuing) | -6.17M | -24.62M | -56.69M | 17.89M | -9.99M | -57.53M | -49.59M | -106.93M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.87▲ 0% | -5.28▼ 506.9% | -3.82▲ 27.7% | 0.87▲ 122.8% | -0.46▼ 152.9% | -2.15▼ 367.4% | -0.80▲ 62.8% | -0.12▲ 0% |
EPS Growth % | - | -506.9% | 27.65% | 122.77% | -152.87% | -367.39% | 62.79% | 32.47% |
EPS (Basic) | -0.87 | -5.28 | -3.82 | 0.90 | -0.46 | -2.15 | -0.80 | - |
Diluted Shares Outstanding | 7.09M | 4.66M | 14.85M | 20.6M | 21.59M | 26.72M | 622.22M | 868.91M |
Basic Shares Outstanding | 7.09M | 4.66M | 14.85M | 19.93M | 21.59M | 26.72M | 622.22M | 868.91M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
IRD Balance Sheet
Opus Genetics, Inc. (IRD) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.76M | 17.67M | 26.07M | 48.99M | 53.95M | 36.61M | 50.04M | 66.6M |
Cash & Short-Term Investments | 1.54M | 16.4M | 24.75M | 42.68M | 50.52M | 30.32M | 45.09M | 59.96M |
Cash Only | 1.54M | 16.4M | 24.53M | 42.63M | 50.5M | 30.32M | 45.09M | 59.96M |
Short-Term Investments | 0 | 0 | 219K | 49K | 15K | 2K | 0 | 0 |
Accounts Receivable | 125K | 0 | 0 | 4.85M | 2.33M | 5.77M | 3.17M | 2.71M |
Days Sales Outstanding | - | - | - | 44.42 | 44.7 | 191.66 | 81.38 | 112.22 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 81K | 26K | 71K | 80K | 102K | 515K | 1.79M | 3.93M |
Total Non-Current Assets | 22K | 14K | 10K | 6K | 0 | 252K | 199K | 186K |
Property, Plant & Equipment | 22K | 14K | 10K | 6K | 0 | 252K | 199K | 186K |
Fixed Asset Turnover | - | - | 58.90x | 6641.67x | - | 43.62x | 71.34x | 58.24x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Assets | 1.78M▲ 0% | 17.68M▲ 891.1% | 26.08M▲ 47.5% | 48.99M▲ 87.9% | 53.95M▲ 10.1% | 36.86M▼ 31.7% | 50.24M▲ 36.3% | 66.79M▲ 0% |
Asset Turnover | - | - | 0.02x | 0.81x | 0.35x | 0.30x | 0.28x | 0.25x |
Asset Growth % | - | 891.14% | 47.48% | 87.87% | 10.12% | -31.67% | 36.3% | 50.63% |
Total Current Liabilities | 9.34M | 3.19M | 3.85M | 2.75M | 4.04M | 11.29M | 7.78M | 9.34M |
Accounts Payable | 342K | 1.21M | 1.58M | 1.07M | 2.15M | 3.15M | 3.29M | 4.42M |
Days Payables Outstanding | - | - | - | - | - | - | - | 175.02 |
Short-Term Debt | 5.67M | 0 | 538K | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2.71M | 0 | 0 | 0 | 74K | 2K | 4.49M | 4.12M |
Current Ratio | 0.19x | 5.55x | 6.76x | 17.79x | 13.35x | 3.24x | 6.43x | 7.13x |
Quick Ratio | 0.19x | 5.55x | 6.76x | 17.79x | 13.35x | 3.24x | 6.43x | 7.13x |
Cash Conversion Cycle | - | - | - | - | - | - | - | -62.79 |
Total Non-Current Liabilities | 0 | 27.96M | 0 | 0 | 0 | 18.84M | 27.11M | 103.28M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25.93M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 27.96M | 0 | 0 | 0 | 18.84M | 27.11M | 77.35M |
Total Liabilities | 9.34M | 31.15M | 3.85M | 2.75M | 4.04M | 30.14M | 34.9M | 112.62M |
Total Debt | 5.67M | 0 | 538K | 0 | 0 | 0 | 0 | 25.93M |
Net Debt | 4.13M | -16.4M | -24M | -42.63M | -50.5M | -30.32M | -45.09M | -34.02M |
Debt / Equity | - | - | 0.02x | - | - | - | - | -0.57x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.60x |
Net Debt / EBITDA | - | - | - | -2.34x | - | - | - | 0.79x |
Interest Coverage | -3.38x | -2.60x | -28345.50x | 2023.56x | -7.51x | - | -32.83x | -25.92x |
Total Equity | -7.56M▲ 0% | -13.47M▼ 78.1% | 22.22M▲ 265.0% | 46.24M▲ 108.1% | 49.91M▲ 7.9% | 6.72M▼ 86.5% | 15.35M▲ 128.3% | -45.84M▲ 0% |
Equity Growth % | - | -78.13% | 265.01% | 108.08% | 7.93% | -86.53% | 128.26% | -1014.88% |
Book Value per Share | -1.07 | -2.89 | 1.50 | 2.24 | 2.31 | 0.25 | 0.02 | -0.05 |
Total Shareholders' Equity | -7.56M | -13.47M | 22.22M | 46.24M | 49.91M | 6.72M | 15.35M | -45.84M |
Common Stock | 0 | 1K | 2K | 2K | 2K | 3K | 7K | 7K |
Retained Earnings | -8.05M | -32.67M | -89.37M | -71.48M | -81.47M | -139M | -188.59M | -254.12M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IRD Cash Flow Statement
Opus Genetics, Inc. (IRD) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -3.59M | -6.8M | -19.37M | 14.31M | -1.11M | -25.58M | -35.25M | -38.99M |
Operating CF Margin % | - | - | -3288.62% | 35.92% | -5.84% | -232.68% | -248.33% | - |
Operating CF Growth % | - | -89.17% | -184.98% | 173.9% | -107.77% | -2200% | -37.84% | -134.55% |
Net Income | -6.17M | -24.62M | -56.69M | 17.89M | -9.99M | -57.53M | -49.59M | -106.93M |
Depreciation & Amortization | 3K | 8K | 4K | 4K | 6K | 10K | 53K | 53K |
Stock-Based Compensation | 308K | 1.51M | 1.91M | 1.81M | 3.51M | 3.36M | 3.4M | 1.71M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.91M | 15.16M | 35.22M | 170K | 1.28M | 25.49M | 13.04M | 68.14M |
Working Capital Changes | 357K | 1.15M | 181K | -5.55M | 4.08M | 3.09M | -2.15M | -1.96M |
Change in Receivables | 0 | 0 | 0 | -4.85M | 2.52M | -3.44M | 2.61M | 2.04M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -168K | 792K | 381K | -515K | 1.08M | 220K | 7K | 1.88M |
Cash from Investing | -25K | 539K | -100K | 0 | 0 | 1.21M | 0 | 0 |
Capital Expenditures | -25K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | 0% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 539K | -100K | 0 | 0 | 1.21M | 0 | 0 |
Cash from Financing | 4.7M | 21.12M | 27.61M | 3.79M | 8.98M | 4.19M | 50.02M | 57.15M |
Debt Issued (Net) | 4.71M | 2.2M | 538K | -538K | 0 | 0 | 1M | 1M |
Equity Issued (Net) | 0 | 21.15M | 28.49M | 4.43M | 9.23M | 4.42M | 49.02M | 56.15M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | -79K | -152K | -509K |
Other Financing | -2K | -2.23M | -1.42M | -104K | -248K | -232K | 0 | 0 |
Net Change in Cash | 1.09M▲ 0% | 14.86M▲ 1268.5% | 8.13M▼ 45.3% | 18.1M▲ 122.5% | 7.87M▼ 56.5% | -20.18M▼ 356.5% | 14.77M▲ 173.2% | 18.17M▲ 0% |
Free Cash Flow | -3.62M▲ 0% | -6.8M▼ 87.9% | -19.37M▼ 185.0% | 14.31M▲ 173.9% | -1.11M▼ 107.8% | -25.58M▼ 2200.0% | -35.25M▼ 37.8% | -38.99M▲ 0% |
FCF Margin % | - | - | -3288.62% | 35.92% | -5.84% | -232.68% | -248.33% | -325.34% |
FCF Growth % | - | -87.87% | -184.98% | 173.9% | -107.77% | -2200% | -37.84% | -35.11% |
FCF per Share | -0.51 | -1.46 | -1.30 | 0.69 | -0.05 | -0.96 | -0.06 | -0.04 |
FCF Conversion (FCF/Net Income) | 0.58x | 0.28x | 0.34x | 0.80x | 0.11x | 0.44x | 0.71x | 0.36x |
Interest Paid | 0 | 0 | 2K | 9K | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 344K | 0 | 0 | 0 |
IRD Key Ratios
Opus Genetics, Inc. (IRD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -1295.1% | 52.26% | -20.77% | -203.19% | -449.36% | 6068.79% |
Return on Invested Capital (ROIC) | - | - | 1493.12% | -526.4% | - | - | 87.62% |
Gross Margin | - | 100% | 100% | 100% | 100% | 100% | 49.64% |
Net Margin | - | -9625.3% | 44.89% | -52.42% | -523.4% | -349.33% | -892.36% |
Debt / Equity | - | 0.02x | - | - | - | - | -0.57x |
Interest Coverage | -2.60x | -28345.50x | 2023.56x | -7.51x | - | -32.83x | -25.92x |
FCF Conversion | 0.28x | 0.34x | 0.80x | 0.11x | 0.44x | 0.71x | 0.36x |
Revenue Growth | - | - | 6665.7% | -52.2% | -42.3% | 29.15% | -12.22% |
Related:IRD Dividend History·IRD Revenue History·IRD Price History·IRD P/E History·IRD Financial Ratios·IRD Institutional Holders
IRD SEC Filings & Documents
Opus Genetics, Inc. (IRD) SEC filings — annual & quarterly reports (10-K, 10-Q)
IRD Frequently Asked Questions
Opus Genetics, Inc. (IRD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Opus Genetics, Inc. (IRD) reported $12.0M in revenue for fiscal year 2025.
Opus Genetics, Inc. (IRD) grew revenue by 29.1% over the past year. This is strong growth.
Opus Genetics, Inc. (IRD) reported a net loss of $106.9M for fiscal year 2025.
Dividend & Returns
Opus Genetics, Inc. (IRD) has a return on equity (ROE) of -449.4%. Negative ROE indicates the company is unprofitable.
Opus Genetics, Inc. (IRD) had negative free cash flow of $39.0M in fiscal year 2025, likely due to heavy capital investments.